iCo Therapeutics (ICOTF) Stock Price, News & Analysis

Company Overview

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $0.58 to $0.65
• 50-Day Range: $0.30 to $0.42
• 52-Week Range: $0.80 to $1.82
• Volume: 272,503 shs
• Average Volume: 4,760 shs
• Market Capitalization: $5.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ICOTF
• CUSIP: N/A
• CIK: N/A
• Web: www.icotherapeutics.com
• Phone: (905) 336-6128
• Fax: 604-602-9699
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,110,000.00
• Net Margins: N/A
• Pretax Margin: -4,148.78%
• Return on Equity: N/A
• Return on Assets: -288.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.72
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -8.71

Miscellaneous

• Outstanding Shares: 9,054,000
• Free Float: N/A
• Market Cap: $5.52 million
• Optionable: Not Optionable
• Beta: 2.03